Already have an account? Sign In
SURGE, formerly known as STIMIT, is a biotechnology company founded in 2016 and based in Cambridge, Massachusetts. We specialize in developing innovative immunotherapy delivery methods to improve cancer treatment outcomes. Our primary focus is on a biodegradable hydrogel designed for intraoperative immunotherapy, which aims to extend the release of cancer treatment drugs at surgical tumor resection sites, potentially preventing post-surgical recurrence and metastasis.
As a subsidiary of Drägerwerk, SURGE has raised a total of $78.79 million in funding, demonstrating investor interest in our innovative approach to cancer care. Our team's personal commitment to advancing cancer treatment protocols underscores the company's mission and potential impact in the biotechnology sector.
While there is currently no public information available regarding SURGE's IPO prospects, it's important to note that the biotechnology industry has seen significant investor interest in recent years. Factors that could potentially influence any future IPO decisions for SURGE might include the progress of our clinical trials, regulatory approvals, and overall market conditions for biotech stocks.
Investors interested in the potential of SURGE's innovative cancer treatment technologies should keep an eye on the company's developments and any official announcements regarding future funding rounds or potential public offerings. However, it's crucial to remember that investing in private companies carries inherent risks, and thorough research is essential before making any investment decisions.
Already have an account? Sign In
While SURGE's IPO prospects remain uncertain, investors eager to gain exposure to innovative companies in the energy sector don't have to wait. At Linqto, we offer members access to interests in pre-IPO private companies, including potential leaders in clean energy and sustainable technologies. Our platform allows you to diversify your portfolio with lower minimum investments, potentially benefiting from the growth of emerging industry disruptors before they go public.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.